<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Obesity: Association with cardiovascular disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Obesity: Association with cardiovascular disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Obesity: Association with cardiovascular disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jose R Medina-Inojosa, MD, M.Sc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carl J Lavie, MD, FACC, FACP, FCCP, FESPM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco Lopez-Jimenez, MD, MSc, FACC, FAHA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Cannon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H951824357">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity is an expanding public health problem worldwide, creating a global health epidemic. According to a 2016 World Health Organization (WHO) report, obesity has nearly tripled since 1980 with 1.9 billion adults worldwide who are considered overweight, including 650 million who had obesity. Obesity has long been associated with an increased risk for cardiovascular diseases (CVD). Given the impact of obesity on various aspects of health, efforts at preventing obesity are urgently needed.
        </p>
        <p>
         The evidence supporting obesity as an independent risk factor, possible mechanisms of action, and a brief discussion of the benefit of weight reduction will be reviewed in this topic. The etiology of obesity, other health hazards associated with obesity, and therapy for obesity are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5372.html" rel="external">
          "Obesity in adults: Prevalence, screening, and evaluation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5377.html" rel="external">
          "Obesity in adults: Etiologies and risk factors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1389694301">
         <span class="h1">
          DEFINITION OF OBESITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity can be defined using a number of different parameters, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Body mass index (BMI)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurements of central obesity (including waist circumference and waist-to-hip ratio)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Body composition measurements
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H223411426">
         <span class="h2">
          BMI
         </span>
         <span class="headingEndMark">
          —
         </span>
         BMI is considered the most practical way to evaluate the degree of obesity, although it is not a measure of body composition (body muscle and fat content). Nonetheless, BMI correlates with CVD and all-cause mortality [
         <a href="#rid1">
          1
         </a>
         ]. BMI is calculated from the height and weight as follows:
        </p>
        <p>
         BMI = body weight (in kg) / square of stature (height, in meters) (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         )
        </p>
        <p>
         The most widely accepted BMI classifications of obesity are those from the WHO [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underweight – BMI of &lt;18.5 kg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal weight – BMI of 18.5 to 24.9 kg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overweight – BMI of 25.0 to 29.9 kg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 1 obesity – BMI of 30.0 to 34.9 kg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 2 obesity – BMI of 35.0 to 39.9 kg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 3 or severe obesity – BMI ≥40.0 kg/m
         <sup>
          2
         </sup>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2037850391">
         <span class="h2">
          Measurements of central obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Waist circumference and waist-to-hip ratio are surrogate estimations of visceral adiposity, which is linked to insulin resistance, dyslipidemia, and increased CVD risk [
         <a href="#rid3">
          3
         </a>
         ]. These measures have been associated with CVD outcomes and mortality, and they been have been shown to inform risk assessment when used in combination with BMI categories [
         <a href="#rid4">
          4
         </a>
         ], as they can be better indicators of risk in some populations [
         <a href="#rid4">
          4
         </a>
         ]. Central obesity is defined as follows [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Waist circumference: men &gt;102 cm (40 in); women &gt;88cm (35 in)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Waist-to-hip ratio: men ≥0.90; women ≥0.85
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3315579589">
         <span class="h2">
          Body composition measurements
         </span>
         <span class="headingEndMark">
          —
         </span>
         BMI has clear limitations to discriminate between fat-free mass, a protective factor, and fat mass, a factor associated with adverse outcomes. There seems to be a role for body composition assessment in obesity diagnosis in the general population, and in persons with established CVD [
         <a href="#rid6">
          6-8
         </a>
         ]; however, body composition assessment with accurate and validated methods like air displacement plethysmography (Bodpod) or Dual-energy X-ray absorptiometry (iDexa) are costly, complex, and only readily available in select clinical settings.
        </p>
        <p class="headingAnchor" id="H20453857">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States and many countries worldwide, the prevalence of obesity trends has continued to rise since the 1980s. Among those 20 years of age or older studied from the 2007 to 2008 through 2015 to 2018 National Health and Nutrition Examination Surveys (NHANES), the following trends have been seen [
         <a href="#rid9">
          9,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity has increased from 33.7 percent to 40.6 percent of the population. In men obesity increased from 32.2 percent to 39.9 percent, while in women obesity increased from 35.4 percent to 41.1 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe obesity has increased from 5.7 percent to 8.4 percent.
        </p>
        <p>
        </p>
        <p>
         Data from the 2017 to 2018 NHANES show that the increasing prevalence of obesity has affected both genders and all age groups [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 20 to 39 years
         </strong>
         – 40.3 percent of men and 39.7 percent of women
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 40 to 59 years
         </strong>
         – 46.4 percent of men and 43.3 percent of women
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 60 years and older
         </strong>
         – 42.2 percent of men and 43.3 percent of women
        </p>
        <p>
        </p>
        <p>
         The prevalence of obesity among children in the United States has also been on the rise in most age groups. Among those younger than 20 years of age studied from the 2007-2008 to 2015-2016 National Health and Nutrition Examination Surveys (NHANES), the following trends have been seen [
         <a href="#rid9">
          9-11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 2 to 5 years
         </strong>
         – Obesity increased from 10.1 to 13.4 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 6 to 11 years
         </strong>
         – Obesity increased slightly from 19.6 percent to 20.3 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ages 12 to 19 years
         </strong>
         – Obesity increased from 18.1 percent to 21.2 percent.
        </p>
        <p>
        </p>
        <p>
         This high prevalence of obesity is observed in many countries. The 2013 Global Burden of Disease Study reported the following trends from 1980 to 2013 [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults, the prevalence of overweight and obesity combined increased from 28.8 percent to 36.9 percent in men and 29.8 percent to 38.0 percent in women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In high-income countries, more men than women were in the overweight and obese weight range, whereas in resource-limited countries, the converse was observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In children and adolescents – The prevalence of overweight and obesity increased in high-income countries from 16.9 to 23.8 percent in boys and 16.2 percent to 22.6 percent in girls.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In children and adolescents – The prevalence of overweight and obesity combined increased in resource-limited countries from 8.1 to 12.9 percent in boys and 8.4 to 13.4 percent in girls.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all ages, prevalence was higher in resource-limited countries than in developing countries.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2018571995">
         <span class="h1">
          MECHANISM OF RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         The demonstration that a physical characteristic, biochemical finding, or lifestyle habit is associated with an increased risk of CVD does not by itself establish a causal relationship. A risk factor may be a primary causal agent (ie, low-density lipoprotein [LDL] cholesterol), or a facilitating causal agent (ie, hypertension, diabetes, and cigarette smoking). Obesity should be viewed in the latter category. Thus, it probably interacts with other risk factors to varying degrees in each individual.
        </p>
        <p>
         There are a number of physiologic and metabolic changes associated with obesity that may contribute to an increased risk of CVD (see
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insulin resistance and hyperinsulinemia
         </strong>
         – Central obesity is associated with insulin resistance and an array of metabolic and hemodynamic disorders, including hyperinsulinemia, atherogenic blood lipid changes, hypertension, and type 2 diabetes. This constellation of findings has been called the metabolic syndrome (or insulin resistance syndrome or syndrome X). Patients who have metabolic syndrome have a threefold increased risk for developing CHD or stroke [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type 2 diabetes mellitus is strongly associated with obesity in all ethnic groups. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related deaths. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences", section on 'Diabetes mellitus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lipid abnormalities
         </strong>
         – These include lower high-density lipoprotein (HDL) level, higher triglyceride level, smaller LDL particles, and increased apolipoprotein B level. Obesity is associated with several atherogenic changes in lipid metabolism, including high serum concentrations of total cholesterol, LDL cholesterol, very-low-density lipoprotein (VLDL)-cholesterol, triglycerides, and a reduction in serum HDL cholesterol of approximately 5 percent [
         <a href="#rid14">
          14,15
         </a>
         ]. The last effect may be most important since a low serum HDL cholesterol concentration carries a greater relative risk of CHD than hypertriglyceridemia. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension –
         </strong>
         Blood pressure is often increased in people with obesity [
         <a href="#rid16">
          16
         </a>
         ]. In the Swedish Obesity Study, for example, hypertension was present at baseline in approximately one-half of participants with obesity. In a report from the Nurses' Health Study, the BMI at age 18 years and at midlife was positively associated with the occurrence of hypertension [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Left ventricular remodeling –
         </strong>
         Obesity is associated with volume overload resulting in adverse changes in left ventricular parameters such as a high end-diastolic volume and increased filling pressure. This, coupled with hypertension, can lead to left ventricular hypertrophy, LVH [
         <a href="#rid18">
          18
         </a>
         ], which is important clinically because it is associated with an enhanced incidence of HF, ventricular arrhythmias, death following MI, and SCD.
        </p>
        <p>
        </p>
        <p>
         In a cross-sectional study of 3500 adults, central obesity measured by waist circumference was associated with abnormal cardiac mechanics (ie, impaired echocardiographic systolic and diastolic strain) [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5298.html" rel="external">
          "Tissue Doppler echocardiography", section on 'Strain and strain rate imaging'
         </a>
         and
         <a class="local">
          'Measurements of central obesity'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sleep disorder
         </strong>
         s – Inadequate sleep, daytime sleepiness, and recurrent circadian disruption induced by night-shift work adversely affect cardiovascular regulation [
         <a href="#rid20">
          20-23
         </a>
         ]. In addition, obesity is associated with obstructive sleep apnea, which is related to excess mortality, hypertension, atrial fibrillation, other arrhythmias, heart failure, coronary artery disease, stroke, and pulmonary hypertension [
         <a href="#rid24">
          24,25
         </a>
         ]. Obstructive sleep apnea and cardiovascular disease are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">
          "Obstructive sleep apnea and cardiovascular disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased systemic inflammation
         </strong>
         –
         <strong>
         </strong>
         Obesity is independently associated with increases in inflammatory markers that mediate the association with CVD risk [
         <a href="#rid26">
          26
         </a>
         ]. C-reactive protein (CRP) is both the most extensively studied marker of inflammation in obesity and the most widely used in clinical practice. Epidemiologic studies also suggest a direct link between interleukin (IL)-6 and tumor necrosis factor-alpha and the increased CVD risk in obesity. (see
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sympathetic nervous system activation
         </strong>
         – Sympathetic nervous system activation has been observed in obesity, and the consequences include hypertension and increased afterload, probably attributable to activation of the sympathetic outflow to the kidneys and insulin resistance [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endothelial dysfunction
         </strong>
         – Endothelial dysfunction is the inability of the endothelium to optimally regulate vascular tone, hemostasis, and vascular inflammation. Endothelial dysfunction in obesity is mainly determined by systemic inflammation, nitric oxide (NO)-bioavailability, oxidized LDL and insulin resistance (see
         <a class="medical medical_review" href="/z/d/html/1532.html" rel="external">
          "Coronary endothelial dysfunction: Clinical aspects"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H468330324">
         <span class="h1">
          ASSOCIATION OF OBESITY WITH VARIOUS CONDITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite uncertainties about the relationship between obesity and CVD, the current guidelines identify obesity as an independent risk factor [
         <a href="#rid28">
          28
         </a>
         ]. This action should heighten clinician awareness about the importance of obesity and stimulate a more vigorous approach to prevention and treatment that takes fat distribution and risk factor prevalence into account. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H783926957">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity has been associated with increased total mortality in a variety of cohorts [
         <a href="#rid29">
          29-33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective cohort study of over one million adults without a history of coronary heart disease (CHD) who were followed for 14 years, obesity was strongly associated with an increased risk of all-cause mortality and CVD death [
         <a href="#rid33">
          33
         </a>
         ]. All-cause mortality was lowest in adults with a body mass index (BMI) between 23.5 and 24.9 kg/m
         <sup>
          2
         </sup>
         in men and 22 and 23.4 kg/m
         <sup>
          2
         </sup>
         in women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Nurses' Health Study, which evaluated the relationship between BMI and total cause specific mortality in 115,195 women from the United States, there was a significant trend for increasing risk of death with increasing BMI [
         <a href="#rid29">
          29
         </a>
         ]. Compared with women with a BMI &lt;19.0 kg/m
         <sup>
          2
         </sup>
         , the relative risk of death was: 1.2 for a BMI of 19.0 to 24.9 kg/m
         <sup>
          2
         </sup>
         ; 1.3 for a BMI of 25.0 to 26.9 kg/m
         <sup>
          2
         </sup>
         ; 1.6 for a BMI of 27 to 28.9 kg/m
         <sup>
          2
         </sup>
         ; and 2.1 to 2.2 for a BMI &gt;29.0 kg/m
         <sup>
          2
         </sup>
         . The risk of death was increased at BMI levels well below those considered to indicate obesity, with a striking increase in risk for truly women with obesity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2013 systematic review and meta-analysis of 97 studies compared all-cause mortality for persons with overweight and obesity with persons with normal BMI [
         <a href="#rid31">
          31
         </a>
         ]. The findings suggested increased mortality rates with obesity, although only statistically significant with grade 2 to 3 obesity. Additionally they observed lower-mortality individuals with BMI in the overweight range. (See
         <a class="local">
          'Definition of obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, in a meta-analysis of 239 prospective studies across four continents, which examined the association of BMI categories with all-cause mortality, there was a linear relationship between greater BMI and mortality. When restricting the analysis to patients who had never smoked and did not have baseline CVD on the first five years of follow-up, a BMI of 25 kg/m
         <sup>
          2
         </sup>
         or more was associated with greater all-cause mortality (hazard ratio 1.31 per 5 kg/m
         <sup>
          2
         </sup>
         units higher BMI) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H262884439">
         <span class="h2">
          Obesity and CHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is strong, consistent epidemiologic evidence for an association between obesity and CHD, with significant risk associated with obesity beginning as early as childhood [
         <a href="#rid34">
          34-37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management", section on 'Mortality'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As an example, the Munster Heart Study (PROCAM) followed 16,288 men and 7325 women for up to seven years [
         <a href="#rid35">
          35
         </a>
         ]. There was a graded positive relationship between BMI and other CHD risk factors including age, total serum cholesterol, low-density lipoprotein (LDL) cholesterol, and systolic and diastolic blood pressure in addition to markers of inflammation and thrombosis. The increase of CHD death associated with BMI was completely accounted for and mediated by these risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of studies assessing the impact of body weight on CHD, there was a 29 percent increase in CHD for each five-unit increase in BMI. The risk of CHD in persons with overweight and obesity is compounded by the frequent coexistence of other CHD risk factors such as hypertension, dyslipidemia, and diabetes. How much of the risk is due to obesity alone has been uncertain [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3406471574">
         <span class="h3">
          Abdominal obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         At any given level of BMI, the risk of the development of CVD in both men and women is increased with central obesity [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5372.html" rel="external">
          "Obesity in adults: Prevalence, screening, and evaluation", section on 'Waist circumference'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The relationship between abdominal obesity and CVD mortality was evaluated in a cohort of 44,636 women in the Nurses' Health Study [
         <a href="#rid39">
          39
         </a>
         ]. The relative risk increased significantly from the lowest to the highest waist circumference quintiles (1.00, 1.04, 1.04, 1.28, and 1.99 respectively) after adjustment for BMI and other confounders during 16 years of follow-up. This relationship persisted even among normal weight women (BMI 18.5 to &lt;25 kg/m
         <sup>
          2
         </sup>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 27,098 patients in 52 countries which compared BMI and waist-to-hip ratio and associated risk of MI. BMI showed a modest association with MI (odds ratio [OR] 1.44, 95% CI 1.32-1.57), which was substantially reduced after adjustment for waist-to-hip ratio (OR 1.12, 95% CI 1.03-1.22) For waist-to-hip ratio, the ORs for every successive quintile were significantly greater than that of the previous one (fourth quintile OR 1.90, 95% CI 1.74-2.07; and fifth quintile OR 2.52, 95% CI 2.31-2.74) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prognostic effect of combining BMI and measures of central obesity with total CVD mortality was studied in the NHANES III. For example, a man with a normal BMI and central obesity had nearly twofold greater total mortality risk than a man with similar BMI but no central obesity, and this patient had twice the mortality risk of participants who were overweight or obese according to BMI only. Similar findings were noted in women [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39337353">
         <span class="h2">
          Heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the association with CHD, there is an important association between obesity and heart failure (HF), especially HF with preserved ejection fraction [
         <a href="#rid26">
          26,41-43
         </a>
         ]  (
         <a class="graphic graphic_figure graphicRef121464" href="/z/d/graphic/121464.html" rel="external">
          figure 1
         </a>
         ). In an analysis from the Framingham Heart Study, in which almost 6000 individuals without a history of HF (mean age 55 years) were followed for a mean of 14 years, the risk of HF was increased approximately twofold in subjects with obesity compared with non-obese subjects [
         <a href="#rid44">
          44
         </a>
         ]. After adjusting for established risk factors (ie, hypertension, CHD, diabetes, left ventricular hypertrophy [LVH]), the risk for HF increased 5 percent in men and 7 percent in women for each increment of 1 kg/m
         <sup>
          2
         </sup>
         in BMI. (See
         <a class="medical medical_review" href="/z/d/html/3479.html" rel="external">
          "Epidemiology of heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4166411869">
         <span class="h2">
          Atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF)
         <strong>
         </strong>
         is the most common arrhythmia in adults, with prevalence rates that are expected to rise by threefold in the next few decades [
         <a href="#rid45">
          45
         </a>
         ]. Several obesity-related factors contribute to this epidemic of AF; obesity leads to left atrial remodeling via various mechanisms, and it is associated with a marked increase in the risk of developing AF. The ARIC (Atherosclerosis Risk In Communities) study estimated that one in five cases of AF can be attributed to obesity [
         <a href="#rid46">
          46
         </a>
         ]. Conversely, as observed in other CVDs, it has been suggested that while obesity increases the risk for incident AF, overweight and obese patients with AF seem to have a better prognosis, including a lower CVD and all-cause mortality, compared to lean AF patients, suggesting an obesity paradox [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1436940366">
         <span class="h2">
          Sudden cardiac death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whereas the most commonly reported cause of death in patients with obesity is HF, there is growing evidence of an increased risk of sudden cardiac death (SCD) in people with obesity [
         <a href="#rid47">
          47
         </a>
         ]. Individuals with an elevated BMI or central obesity are more likely to have prolonged QT intervals, and this has been proposed as a potential mechanism for SCD in people with obesity, in addition to the increased risk for CHD [
         <a href="#rid48">
          48
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p class="headingAnchor" id="H842047441">
         <span class="h1">
          METABOLICALLY "HEALTHY" OBESITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A phenotype called metabolically "healthy" obesity (MHO) refers to obese individuals who have relatively normal levels of plasma lipids, glucose, and blood pressure. While historically it has been unclear as to whether these individuals are at an increased risk of CVD, especially CHD [
         <a href="#rid49">
          49
         </a>
         ], evidence suggests that these individuals tend to develop metabolic dysregulation and likely have increased cardiovascular risk in the long-term [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2013 meta-analysis of eight studies (61,386 adults with nearly 4000 adverse cardiac events over more than 10 years of follow-up), obese adults, including those without significant metabolic derangements, were at increased risk for adverse events compared with metabolically healthy normal weight adults [
         <a href="#rid52">
          52
         </a>
         ]. Adults with obesity who were metabolically healthy (defined as the absence of components of the metabolic syndrome) had a 24 percent increased risk for increased events compared with metabolically healthy adults in the normal weight range.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from the Copenhagen General Population Study suggest that being in the overweight or obese weight range increases the risk for myocardial infarction (MI) and ischemic heart disease, irrespective of the presence or absence of criteria for the metabolic syndrome [
         <a href="#rid53">
          53
         </a>
         ]. In this study of 71,527 adults (median follow-up 3.6 years), adults in the overweight or obese BMI categories without metabolic syndrome had an increased risk for MI compared with adults in the normal BMI range without metabolic syndrome (adjusted hazard ratio [HR] 1.26; 95% CI 1.0-1.61 for persons with overweight; HR 1.88; 95% CI 1.3-2.6 for persons with obesity).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An analysis of the contemporary Multi-Ethic Study of Atherosclerosis followed 6809 subjects for 12.2 years, and reported that even though those with MHO did not have an increased risk of incident CVD, nearly half of these individuals developed metabolic abnormalities and subsequently developed increased CVD risk [
         <a href="#rid50">
          50
         </a>
         ]. Similar findings were observed in the Whitehall II cohort study of British adults, where over 20 years of follow-up, a high number of those with MHO eventually developed "metabolic un-healthiness" [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A large study of electronic health records (1995 to 2015) in The Health Improvement Network (THIN) that included 3.5 million adults free of established CVD at baseline, with and without metabolic abnormalities. During follow-up of 5.4 years, individuals with obesity and no metabolic abnormalities had a higher risk of CHD (multivariate-adjusted HR 1.49; 95% CI 1.45-1.54), cerebrovascular disease (HR 1.07; 95% CI 1.04-1.11), and HF (HR 1.96; 95% CI 1.86 -2.06) compared with individuals with normal weight and no metabolic abnormalities. An increasing number of metabolic abnormalities increased risks of CHD, cerebrovascular disease, and HF in individuals with normal weight, overweight, and obesity [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4159709791">
         <span class="h1">
          OBESITY PARADOX
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although obesity increases the risk for a number of established CVD risk factors, persons with overweight or obesity and established CHD may have better prognosis compared with persons in the normal weight range who have CHD. This phenomenon has been referred to as the "obesity paradox." The obesity paradox is seen in many forms of CVD and also other diseases, such as end-stage kidney disease, human immunodeficiency virus and various pulmonary diseases [
         <a href="#rid56">
          56
         </a>
         ]. Although the obesity paradox has been observed for most CVDs, it most likely applies to persons in the overweight, grade I obesity, and less for grade II or greater obesity categories. The possible explanations for the obesity paradox include reverse causality (patients in the underweight or normal weight range are sicker), the inability of BMI to distinguish fat tissue from muscle mass, and even the possibility that adipose tissue may provide protection during acute severe illnesses where caloric intake is severely disrupted. The evidence for an obesity paradox is mixed for individuals with BMI between 22 and 24.9, but the evidence showing increased mortality in individuals with lower BMI values is indisputable. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management", section on 'Mortality'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AF Follow-up Investigation of Rhythm Management (AFFIRM) trial, patients with higher BMI had lower all-cause mortality than normal-weight patients over a three-year follow-up period (adjusted HR 0.77; 95% CI 0.62-0.95) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 2625 participants with new-onset diabetes mellitus in five longitudinal cohort studies, all-cause mortality rates were higher among people in the normal weight versus overweight/obesity categories (adjusted HR 2.08, 95% CI 1.52-2.85) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using data from the Nurses' Health Study and Health Professional Follow-up Study to examine the relationship between BMI and all-cause mortality among men and women with diabetes, there was no evidence of an obesity paradox in diabetic men and women [
         <a href="#rid59">
          59
         </a>
         ]. Participants with a BMI between 22.5 and 24.9 had the lowest mortality.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3771257266">
         <span class="h1">
          BENEFITS OF WEIGHT LOSS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss improves or prevents many of the obesity-related risk factors for CVD [
         <a href="#rid60">
          60
         </a>
         ]. Benefits include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased blood pressure in patients with hypertension [
         <a href="#rid61">
          61,62
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased incidence of diabetes mellitus [
         <a href="#rid63">
          63,64
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved lipid profile [
         <a href="#rid65">
          65
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased insulin resistance [
         <a href="#rid64">
          64
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced C-reactive protein concentration [
         <a href="#rid61">
          61
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improved endothelial function [
         <a href="#rid66">
          66
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Achieving and maintaining weight loss is made difficult by the reduction in energy expenditure that is induced by weight loss. In addition, recidivism (regaining of lost weight) is a common problem. Of those patients who lose weight during any treatment program, most do not maintain the weight loss. Importantly, physical activity may be more important than achieving a normal BMI in patients with CHD. Changes in physical activity correlate with better survival whereas changes in BMI, including weight loss, do not [
         <a href="#rid67">
          67,68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management", section on 'Importance of weight loss'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise"
         </a>
         .)
        </p>
        <p>
         Health care providers should urge patients to lose weight, especially if accomplished with increases in physical activity and improvements in cardiorespiratory fitness. Prevention of obesity beginning in early life may be perhaps the best strategy to reduce the burden of CVD in the population. In obese older adults, recommendations for weight loss are controversial. Moderate weight loss may have beneficial effects on comorbidities, functional performances, and quality of life provided that regular physical activity can be associated [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Drug therapy may be a helpful component of treatment for persons in the overweight BMI category. However, among patients with CVD, certain drugs may be contraindicated. Anti-obesity drugs have been used as an adjunct to diet and exercise for obese subjects with a BMI greater than 30 kg/m
         <sup>
          2
         </sup>
         . The role of drug therapy has been questioned, however, because of concerns about long term effectiveness, the potential for abuse, and side effects. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         .)
        </p>
        <p>
         Bariatric procedures are an option for patients at high risk of complications from obesity and have shown to be relatively safe and effective [
         <a href="#rid70">
          70
         </a>
         ]. Major examples on the benefit of significant weight loss can be observed in patients that undergo bariatric procedures (gastric bypass or banding) that reduce CVD risk factors, including metabolic components (blood pressure, diabetes incidence, improve lipid profiles) and clinical outcomes (improvements in quality of life [
         <a href="#rid71">
          71
         </a>
         ], non-fatal CVD outcomes [
         <a href="#rid71">
          71
         </a>
         ], and lower mortality [
         <a href="#rid72">
          72
         </a>
         ]). These benefits do not appear to occur with liposuction [
         <a href="#rid73">
          73
         </a>
         ], suggesting that the negative energy balance associated with decreased nutritional intake may be necessary for achieving the metabolic benefits of weight loss. (See
         <a class="medical medical_review" href="/z/d/html/586.html" rel="external">
          "Bariatric surgery for management of obesity: Indications and preoperative preparation"
         </a>
         .)
        </p>
        <p>
         The ACC/AHA guidelines for the management of patients with stable ischemic heart disease made the following recommendations for weight management [
         <a href="#rid74">
          74
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular assessment of BMI and recommend assessing waist circumference at all BMI levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Counseling on weight management at each patient visit, with a goal of a BMI between 18.5 and 24.9 kg/m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The initial goal of weight loss should be approximately 10 percent from baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lifestyle changes and consideration of treatment strategies for metabolic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1493992744">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83815.html" rel="external">
          "Patient education: Health risks of obesity (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15486.html" rel="external">
          "Patient education: Weight loss treatments (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1988.html" rel="external">
          "Patient education: Losing weight (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4065113172">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111343.html" rel="external">
          "Society guideline links: Primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115645.html" rel="external">
          "Society guideline links: Secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/123097.html" rel="external">
          "Society guideline links: Lifestyle management and cardiac rehabilitation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111344.html" rel="external">
          "Society guideline links: Obesity in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1613546774">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Obesity is an expanding public health problem worldwide, with a near tripling of the prevalence of worldwide obesity since 1980. Given the impact of obesity on various aspects of health, efforts at preventing obesity are urgently needed. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Body mass index (BMI) is the most practical way to evaluate the degree of obesity, although it is not a measure of body composition. Nonetheless, BMI correlates with cardiovascular disease (CVD) and all-cause mortality. BMI is equal to body weight (in kilograms) divided by square of stature (height, in meters). Overweight is defined as a BMI between 25.0 and 29.9 kg/m
         <sup>
          2
         </sup>
         and obesity as a BMI greater than 30 kg/m
         <sup>
          2
         </sup>
         . (See
         <a class="local">
          'BMI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms of risk
         </strong>
         – There are a number of physiologic and metabolic changes associated with obesity that may contribute to an increased risk of CVD, including insulin resistance and hyperinsulinemia, type 2 diabetes mellitus, lipid abnormalities, hypertension, obstructive sleep apnea, systemic inflammation, sympathetic nervous system activation, and endothelial dysfunction. (See
         <a class="local">
          'Mechanism of risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obesity and cardiac outcomes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abdominal obesity and CVD – At any given level of BMI, the risk of the development of CVD in both men and women is increased by greater amounts of abdominal fat, resulting in an increased waist circumference or waist to hip ratio (See
         <a class="local">
          'Measurements of central obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity is an independent risk factor for the development of CVD, although the exact extent of the relationship has been variable in different populations of patients. Obesity is also associated with a greater risk of overall and CVD mortality as well as the development of HF. (See
         <a class="local">
          'Association of obesity with various conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolically "healthy" obesity
         </strong>
         – This refers to obese individuals who have relatively normal levels of plasma lipids, glucose, and blood pressure. While historically it has been unclear as to whether these individuals are at an increased risk of CVD, especially CHD, evidence suggests that these individuals tend to develop metabolic dysregulation and likely have increased cardiovascular risk in the long-term. (See
         <a class="local">
          'Metabolically "healthy" obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits of weight loss
         </strong>
         – Health care providers need to encourage patients with known CVD or CVD risk factors (ie, hypertension, dyslipidemia, type 2 diabetes mellitus) to lose weight, especially with physical activity and exercise training that increases levels of cardiorespiratory fitness. Dietary and lifestyle modifications should be the initial approach in the majority of patients, with pharmacologic and surgical therapy considered in selected patients. (See
         <a class="local">
          'Benefits of weight loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2728561304">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Melvyn Rubenfire, MD, Elizabeth Jackson, MD, MPH, and Geoffrey Barnes, MD, MSc, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ortega FB, Sui X, Lavie CJ, Blair SN. Body Mass Index, the Most Widely Used But Also Widely Criticized Index: Would a Criterion Standard Measure of Total Body Fat Be a Better Predictor of Cardiovascular Disease Mortality? Mayo Clin Proc 2016; 91:443.
          </a>
         </li>
         <li class="breakAll">
          https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. (Accessed on May 28, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medina-Inojosa JR, Batsis JA, Supervia M, et al. Relation of Waist-Hip Ratio to Long-Term Cardiovascular Events in Patients With Coronary Artery Disease. Am J Cardiol 2018; 121:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med 2015; 163:827.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 2008. World Health Organization 2011.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medina-Inojosa JR, Somers VK, Thomas RJ, et al. Association Between Adiposity and Lean Mass With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: No Paradox. J Am Heart Assoc 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowles R, Carter J, Jebb SA, et al. Associations of Skeletal Muscle Mass and Fat Mass With Incident Cardiovascular Disease and All-Cause Mortality: A Prospective Cohort Study of UK Biobank Participants. J Am Heart Assoc 2021; 10:e019337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonikowske AR, Barillas Lara MI, Koepp KE, et al. Fat Mass Index Better Identifies Metabolic Syndrome: Insights from Patients in Early Outpatient Cardiac Rehabilitation. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hales CM, Fryar CD, Carroll MD, et al. Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. JAMA 2018; 319:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation 2022; 145:e153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief 2020; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy SM, Barnett JP. Metabolic and health complications of obesity. Dis Mon 1990; 36:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993; 306:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch R, Sharma AM. Obesity and cardiovascular hemodynamic function. Curr Hypertens Rep 1999; 1:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg PK, Biggs ML, Kizer JR, et al. Associations of body size and composition with subclinical cardiac dysfunction in older individuals: the cardiovascular health study. Int J Obes (Lond) 2021; 45:2539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxton OM, Cain SW, O'Connor SP, et al. Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption. Sci Transl Med 2012; 4:129ra43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009; 106:4453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Covassin N, Bock JM, et al. Excessive Daytime Sleepiness and Cardiovascular Mortality in US Adults: A NHANES 2005-2008 Follow-Up Study. Nat Sci Sleep 2021; 13:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narkiewicz K, Somers VK. Obstructive sleep apnea as a cause of neurogenic hypertension. Curr Hypertens Rep 1999; 1:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144:e56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie CJ, Laddu D, Arena R, et al. Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018; 72:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esler M, Straznicky N, Eikelis N, et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63:2985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med 1985; 103:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte H, Cullen P, Assmann G. Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis 1999; 144:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007; 167:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999; 103:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol 2006; 35:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Rexrode KM, van Dam RM, et al. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 2008; 117:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie CJ, Arena R, Alpert MA, et al. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol 2018; 15:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davos CH, Doehner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003; 9:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie CJ, Pandey A, Lau DH, et al. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise. J Am Coll Cardiol 2017; 70:2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adabag S, Huxley RR, Lopez FL, et al. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart 2015; 101:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finocchiaro G, Papadakis M, Dhutia H, et al. Obesity and sudden cardiac death in the young: Clinical and pathological insights from a large national registry. Eur J Prev Cardiol 2018; 25:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berstein LM. Dark and light side of obesity: mortality of metabolically healthy obese people. Expert Rev Endocrinol Metab 2012; 7:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. J Am Coll Cardiol 2018; 71:1857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deedwania P, Lavie CJ. Dangers and Long-Term Outcomes in Metabolically Healthy Obesity: The Impact of the Missing Fitness Component. J Am Coll Cardiol 2018; 71:1866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med 2014; 174:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell JA, Hamer M, Batty GD, et al. Incidence of Metabolic Risk Factors Among Healthy Obese Adults: 20-Year Follow-Up. J Am Coll Cardiol 2015; 66:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol 2017; 70:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elagizi A, Kachur S, Lavie CJ, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis 2018; 61:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014; 370:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110:2952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008; 168:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med 1998; 158:2477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothberg AE, McEwen LN, Kraftson AT, et al. Impact of weight loss on waist circumference and the components of the metabolic syndrome. BMJ Open Diabetes Res Care 2017; 5:e000341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavie CJ, Ortega FB, Kokkinos P. Impact of Physical Activity and Fitness in Metabolically Healthy Obesity. J Am Coll Cardiol 2018; 71:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moholdt T, Lavie CJ, Nauman J. Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study. Am J Med 2017; 130:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmon P. Intentional weight loss in older adults: useful or wasting disease generating strategy? Curr Opin Clin Nutr Metab Care 2013; 16:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, et al. Safety and efficacy of bariatric surgery in patients with coronary artery disease. Mayo Clin Proc 2005; 80:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batsis JA, Lopez-Jimenez F, Collazo-Clavell ML, et al. Quality of life after bariatric surgery: a population-based cohort study. Am J Med 2009; 122:1055.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1529 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26948431" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Body Mass Index, the Most Widely Used But Also Widely Criticized Index: Would a Criterion Standard Measure of Total Body Fat Be a Better Predictor of Cardiovascular Disease Mortality?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26948431" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Body Mass Index, the Most Widely Used But Also Widely Criticized Index: Would a Criterion Standard Measure of Total Body Fat Be a Better Predictor of Cardiovascular Disease Mortality?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29482851" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relation of Waist-Hip Ratio to Long-Term Cardiovascular Events in Patients With Coronary Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26551006" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26551006" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29739793" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Association Between Adiposity and Lean Mass With Long-Term Cardiovascular Events in Patients With Coronary Artery Disease: No Paradox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33870707" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Associations of Skeletal Muscle Mass and Fat Mass With Incident Cardiovascular Disease and All-Cause Mortality: A Prospective Cohort Study of UK Biobank Participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31817309" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fat Mass Index Better Identifies Metabolic Syndrome: Insights from Patients in Early Outpatient Cardiac Rehabilitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29570750" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35078371" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32487284" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24880830" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11315831" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cardiovascular morbidity and mortality associated with the metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6219830" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2261844" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Metabolic and health complications of obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8362892" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Obesity and the heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9441586" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Body weight, weight change, and risk for hypertension in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10981053" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Obesity and cardiovascular hemodynamic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34349227" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Associations of body size and composition with subclinical cardiac dysfunction in older individuals: the cardiovascular health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22496545" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adverse metabolic consequences in humans of prolonged sleep restriction combined with circadian disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255424" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adverse metabolic and cardiovascular consequences of circadian misalignment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23589584" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Increased prevalence of sleep-disordered breathing in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34262376" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Excessive Daytime Sleepiness and Cardiovascular Mortality in US Adults: A NHANES 2005-2008 Follow-Up Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10981077" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Obstructive sleep apnea as a cause of neurogenic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34148375" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30236314" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Healthy Weight and Obesity Prevention: JACC Health Promotion Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000932" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mechanisms of sympathetic activation in obesity-related hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239920" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637744" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Body weight and mortality among women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4062116" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Weight and thirty-year mortality of men in the Framingham Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23280227" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27423262" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10511607" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Body-mass index and mortality in a prospective cohort of U.S. adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397319" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381293" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846390" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10353925" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16339600" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : What aspects of body fat are particularly hazardous and how do we measure them?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362231" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16271645" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28748957" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of cardiovascular diseases in patients with obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612870" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11527635" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The relationship between obesity and mortality in patients with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151467" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Obesity and the risk of heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025560" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21444879" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25410499" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29319343" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Obesity and sudden cardiac death in the young: Clinical and pathological insights from a large national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30754122" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Dark and light side of obesity: mortality of metabolically healthy obese people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29699611" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29699612" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dangers and Long-Term Outcomes in Metabolically Healthy Obesity: The Impact of the Missing Fitness Component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297192" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24217719" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26271072" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Incidence of Metabolic Risk Factors Among Healthy Obese Adults: 20-Year Follow-Up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28911506" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29981771" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20609687" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22871870" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Association of weight status with mortality in adults with incident diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24428469" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Body-mass index and mortality among adults with incident type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509809" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466377" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18362248" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212316" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9855386" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28316795" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Impact of weight loss on waist circumference and the components of the metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854119" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29447747" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Impact of Physical Activity and Fitness in Metabolically Healthy Obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28238694" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429407" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Intentional weight loss in older adults: useful or wasting disease generating strategy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178495" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Safety and efficacy of bariatric surgery in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19854336" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Quality of life after bariatric surgery: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10509605" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15201411" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166210" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
